A double-blind, randomized, placebo-controlled trial investigating the efficacy and safety of nerandomilast over at least 52 weeks in patients with fibrosing interstitial lung disease at risk for disease progression (FIBRONEER-ACT)

未提供0 个研究点目标入组 466 人开始时间: 待定

适应症

试验速览

暂无简介。

•Male and female individuals aged 18 years or older at the time of first signed informed consent at Visit 1a
•Signed and dated written informed consent in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Good Clinical Practice (GCP) and local legislation prior to admission to the trial
•Diagnosis of fibrosing interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF) as established by the investigator
•Presence of fibrotic lung disease on high resolution computed tomography (HRCT), defined as reticulation with traction bronchiectasis/ bronchiolectasis and/or honeycombing with fibrosis involving at least 10% of the lung. as assessed by central review prior to randomization
•Time since ILD diagnosis within 3 years before randomization
•FVC with 45% or more of predicted normal at Visit 1
•Diffusing capacity of the lungs for carbon monoxide (DLCO) with 25% and more of predicted normal corrected for hemoglobin (Hb) at Visit 1
•Patients treated with permitted immunosuppressive/immunomodulatory agents for an underlying systemic disease (e.g. methotrexate (MTX), azathioprine (AZA) need to be on stable treatment for at least 12 weeks prior to Visit 1 and during screening period

•Known diagnosis of idiopathic pulmonary fibrosis (IPF) based on multidisciplinary discussion (MDD) and according to the American Thoracic Society (ATS)/European Respiratory Society (ERS) 2022 guidelines
•Known diagnosis of autoimmune-ILDs other than rheumatoid arthritis-associated ILD (RA-ILD)
•Known diagnosis of sarcoidosis
•Patients with predominant features of organizing pneumonia on HRCT, as assessed by central review
•Patients who developed ILD due to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection/Coronavirus Disease 2019 (COVID-19) (based on investigators judgement)
•Meeting criteria for progressive pulmonary fibrosis (PPF), as assessed by investigator
•Meeting criteria for treatment with currently approved therapies for the fibrosing ILD (e.g. PPF), as assessed by investigator
•Prior or current use of nerandomilast, nintedanib, or pirfenidone

发起方

未提供